- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Cellyan Biotechnology Co., Ltd - 20-F, Annual and transition report of foreign private issuers | 2 | SEC Filings | ||
| CELLYAN BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 17.07. | Cellyan Biotechnology Stock Sinks 21% After Hours: Here's What Happened | 1 | Benzinga.com | ||
| 16.07. | Cellyan Biotechnology erhält 180-tägige Fristverlängerung für Nasdaq-Compliance | 1 | Investing.com Deutsch | ||
| 16.07. | Cellyan Biotechnology gets 180-day extension for Nasdaq compliance | 1 | Investing.com | ||
| 16.07. | Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Additional Compliance Grace Period | 155 | GlobeNewswire (Europe) | HONG KONG, July 16, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the "Company"), a leading provider of over the counter ("OTC") pharmaceutical cross-border e-commerce supply... ► Artikel lesen | |
| 16.07. | Cellyan Biotechnology Co., Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 27.03. | Cellyan Biotechnology Co., Ltd - F-1, Registration statement for certain foreign private issuers | 1 | SEC Filings | ||
| 18.03. | Cellyan Biotechnology Co., Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 16.01. | Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency | 286 | GlobeNewswire (Europe) | HONG KONG, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the "Company"), a leading provider of over the counter ("OTC") pharmaceutical cross-border e-commerce supply... ► Artikel lesen | |
| 17.12.25 | Hong Kong Pharma Digital Technology Holdings Limited Announced Results of 2025 Annual Meeting of Stockholders | 1.689 | GlobeNewswire (Europe) | HONG KONG, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ: HKPD) ("HKPD" or the "Company"), a leading provider of over the counter ("OTC") pharmaceutical... ► Artikel lesen |
10 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 49,850 | +0,08 % | DAX vor spannender Woche - und Rekorden? Bayer, Siemens Energy, Commerzbank und Allianz mit ... | Ungeachtet der geopolitischen Krisenherde könnte die überwiegend positiv aufgenommene Berichtssaison der DAX-Konzern auch in der neuen Woche Rückenwind verleihen. Sinkende Ölpreise und starke Quartalszahlen... ► Artikel lesen | |
| GSK | 22,880 | +0,09 % | BERNSTEIN RESEARCH stuft GSK auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat das Kursziel für GSK von 2825 auf 3010 Pence angehoben und die Einstufung auf "Outperform" belassen. Die Nachhaltigkeit des Geschäfts... ► Artikel lesen | |
| CANOPY GROWTH | 0,850 | +0,97 % | Why Rescheduling Might Not Move Canopy Growth's Stock as Much as You Think | ||
| EYEPOINT | 11,900 | -1,65 % | EyePoint, Inc. - 10-Q, Quarterly Report | ||
| FILANA THERAPEUTICS | 0,850 | -1,05 % | Filana Therapeutics, Inc.: Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update | AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for... ► Artikel lesen | |
| COMPASS PATHWAYS | 11,700 | -0,85 % | Warum Lillys 3,8-Milliarden-Dollar-Deal den Psychedelika-Sektor verändert - und warum Emyria jetzt in den Fokus rücken könnte | ||
| SELLAS LIFE SCIENCES | 10,500 | +0,96 % | DesignRush: Brooke Sellas Joins DesignRush Podcast on Social Media's Revenue Risk | Miami, Florida--(Newsfile Corp. - June 23, 2026) - The latest episode of the DesignRush Podcast features Brooke Sellas, founder and CEO of B Squared Media. The episode explores why companies risk... ► Artikel lesen | |
| CORBUS PHARMACEUTICALS | 8,500 | +4,49 % | Corbus Pharmaceuticals Holdings, Inc. - 10-Q, Quarterly Report | ||
| DARE BIOSCIENCE | 1,410 | +0,71 % | Daré Bioscience, Inc.: Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies | Each year, an estimated six million women in the United States acquire a high-risk HPV infection - and there are no FDA-approved treatments DARE-HPV development is backed by a $10 million U.S. government... ► Artikel lesen | |
| CITIUS PHARMACEUTICALS | 0,682 | -0,01 % | Citius Pharmaceuticals, Inc. - 8-K, Current Report | ||
| ELEDON PHARMACEUTICALS | 3,120 | +6,85 % | Natera, Eledon Partner On Kidney Transplant Monitoring Test For Phase 3 Trial; Stock Up | WASHINGTON (dpa-AFX) - Cell-free DNA testing company Natera, Inc. (NTRA) and Eledon Pharmaceuticals, Inc. (ELDN) announced on Thursday that they have entered into a partnership to use Natera's... ► Artikel lesen | |
| EXICURE | 0,915 | 0,00 % | Exicure, Inc.: Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance | WILMINGTON, Del., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) ("Exicure" or the "Company") today announced that it expects to issue 172,058 shares of its common stock to GPCR Therapeutics... ► Artikel lesen | |
| CHINA SXT PHARMACEUTICALS | - | - | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenDE0005118806 11 88 0 Solutions AG 07.08.2026 DE000A41YFQ4 11 88 0 Solutions AG 10.08.2026 Tausch 5:1CA49752E1060 Radiant... ► Artikel lesen | |
| COSMOS HEALTH | 0,200 | -0,89 % | Cosmos Health Inc.: Cosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B Channels | Digital subscription platform brings together the Company's proprietary consumer health products across consumer (B2C) and corporate (B2B) channelsCustomers can begin through one of three paths: a free... ► Artikel lesen | |
| CHAMPIONS ONCOLOGY | 4,360 | 0,00 % | Champions Oncology, Inc.: Champions Oncology Reports Record Annual Revenue of $59 Million | Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA HACKENSACK, NJ / ACCESS Newswire / July 27, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a global leader in clinically relevant oncology... ► Artikel lesen |
Das Unternehmen CELLYAN BIOTECHNOLOGY CO LTD kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,420 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CELLYAN BIOTECHNOLOGY CO LTD finden Sie auf Wallstreet Online.